News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,955 Results
Type
Article (37207)
Company Profile (70)
Press Release (448676)
Multimedia
Podcasts (74)
Webinars (8)
Section
Business (136908)
Career Advice (994)
Deals (22708)
Drug Delivery (92)
Drug Development (60698)
Employer Resources (83)
FDA (14355)
Job Trends (10648)
News (238787)
Policy (24189)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (2126)
Accelerated approval (27)
Adcomms (25)
Allergies (127)
Alliances (31105)
ALS (140)
Alzheimer's disease (1270)
Antibody-drug conjugate (ADC) (230)
Approvals (14573)
Artificial intelligence (377)
Autoimmune disease (114)
Automation (13)
Bankruptcy (214)
Best Places to Work (8260)
BIOSECURE Act (14)
Biosimilars (123)
Biotechnology (46)
Bladder cancer (146)
Brain cancer (58)
Breast cancer (518)
Cancer (3890)
Cardiovascular disease (363)
Career advice (884)
Career pathing (30)
CAR-T (198)
CDC (49)
Celiac Disease (2)
Cell therapy (530)
Cervical cancer (33)
Clinical research (53513)
Collaboration (1078)
Company closure (2)
Compensation (875)
Complete response letters (52)
COVID-19 (2290)
CRISPR (53)
C-suite (594)
Cystic fibrosis (77)
Data (5044)
Decentralized trials (2)
Denatured (26)
Depression (123)
Diabetes (424)
Diagnostics (4573)
Digital health (37)
Diversity (8)
Diversity, equity & inclusion (18)
Drug discovery (141)
Drug pricing (161)
Drug shortages (32)
Duchenne muscular dystrophy (192)
Earnings (62140)
Editorial (55)
Employer branding (11)
Employer resources (80)
Events (63730)
Executive appointments (668)
FDA (17060)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (9)
Frontotemporal dementia (15)
Funding (1025)
Gene editing (118)
Generative AI (33)
Gene therapy (443)
GLP-1 (826)
Government (3989)
Grass and pollen (6)
Guidances (354)
Healthcare (14556)
HIV (49)
Huntington's disease (37)
IgA nephropathy (65)
Immunology and inflammation (185)
Immuno-oncology (46)
Indications (85)
Infectious disease (2502)
Inflammatory bowel disease (134)
Inflation Reduction Act (10)
Influenza (72)
Intellectual property (146)
Interviews (123)
IPO (10645)
IRA (44)
Job creations (2625)
Job search strategy (776)
JPM (45)
Kidney cancer (15)
Labor market (63)
Layoffs (455)
Leadership (28)
Legal (4732)
Liver cancer (89)
Longevity (12)
Lung cancer (580)
Lymphoma (321)
Machine learning (21)
Management (34)
Manufacturing (455)
MASH (136)
Medical device (13730)
Medtech (13779)
Mergers & acquisitions (12750)
Metabolic disorders (1089)
Multiple sclerosis (126)
NASH (17)
Neurodegenerative disease (253)
Neuropsychiatric disorders (74)
Neuroscience (2258)
Neurotech (1)
NextGen: Class of 2026 (4810)
Non-profit (3465)
Now hiring (40)
Obesity (513)
Opinion (262)
Ovarian cancer (137)
Pain (171)
Pancreatic cancer (191)
Parkinson's disease (214)
Partnered (23)
Patents (280)
Patient recruitment (422)
Peanut (49)
People (40126)
Pharmaceutical (16)
Pharmacy benefit managers (22)
Phase 1 (15623)
Phase 2 (23603)
Phase 3 (18813)
Pipeline (4342)
Policy (249)
Postmarket research (1988)
Preclinical (5028)
Press Release (23)
Prostate cancer (196)
Psychedelics (47)
Radiopharmaceuticals (214)
Rare diseases (671)
Real estate (3673)
Recruiting (36)
Regulatory (19268)
Reports (28)
Research institute (1933)
Resumes & cover letters (129)
Rett syndrome (26)
RNA editing (13)
RSV (67)
Schizophrenia (136)
Series A (156)
Series B (126)
Service/supplier (3)
Sickle cell disease (72)
Special edition (16)
Spinal muscular atrophy (143)
Sponsored (21)
Startups (2571)
Stomach cancer (17)
Supply chain (84)
Tariffs (68)
The Weekly (47)
Vaccines (851)
Venture capital (60)
Weight loss (361)
Women's health (66)
Worklife (13)
Date
Today (113)
Last 7 days (425)
Last 30 days (1485)
Last 365 days (21522)
2026 (2345)
2025 (21694)
2024 (25149)
2023 (28475)
2022 (37082)
2021 (39631)
2020 (38595)
2019 (33891)
2018 (26079)
2017 (23512)
2016 (22269)
2015 (25803)
2014 (19642)
2013 (16081)
2012 (17501)
2011 (17828)
2010 (16335)
Location
Africa (551)
Alabama (40)
Alaska (3)
Arizona (198)
Arkansas (10)
Asia (30767)
Australia (6336)
California (7372)
Canada (2507)
China (910)
Colorado (339)
Connecticut (334)
Delaware (276)
Europe (62415)
Florida (1186)
Georgia (265)
Hawaii (1)
Idaho (43)
Illinois (670)
India (45)
Indiana (425)
Iowa (15)
Japan (348)
Kansas (104)
Kentucky (27)
Louisiana (20)
Maine (57)
Maryland (1034)
Massachusetts (5184)
Michigan (208)
Minnesota (500)
Mississippi (6)
Missouri (100)
Montana (35)
Nebraska (22)
Nevada (90)
New Hampshire (74)
New Jersey (2298)
New Mexico (13)
New York (2117)
North Carolina (1003)
North Dakota (5)
Northern California (3561)
Ohio (238)
Oklahoma (12)
Oregon (32)
Pennsylvania (1634)
Puerto Rico (15)
Rhode Island (37)
South America (771)
South Carolina (61)
Southern California (2955)
Tennessee (129)
Texas (1279)
United States (27606)
Utah (234)
Vermont (1)
Virginia (170)
Washington D.C. (70)
Washington State (543)
West Virginia (4)
Wisconsin (81)
Wyoming (1)
485,955 Results for "mel mont medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.
September 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
January 7, 2026
·
1 min read
Press Releases
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 8, 2026
·
5 min read
Press Releases
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
December 16, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - November 3, 2025
November 4, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
January 7, 2026
·
13 min read
Press Releases
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025
·
21 min read
Press Releases
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 3, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
December 16, 2025
·
12 min read
Press Releases
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
September 15, 2025
·
7 min read
1 of 48,596
Next
